|
KR101483215B1
(ko)
*
|
2010-01-29 |
2015-01-16 |
한미약품 주식회사 |
단백질 키나아제 저해활성을 갖는 비시클릭 헤테로아릴 유도체
|
|
MX358682B
(es)
*
|
2010-07-13 |
2018-08-31 |
Hoffmann La Roche |
Derivados de pirazolo [1,5a]pirimidina y de tieno[3,2b] pirimidina como moduladores de la cinasa asociada al receptor de la interleucina 4 (irak4).
|
|
EP2663312B1
(en)
|
2011-01-10 |
2017-10-11 |
Nimbus Iris, Inc. |
Irak inhibitors and uses thereof
|
|
EP2688872A4
(en)
*
|
2011-03-22 |
2014-08-27 |
Merck Sharp & Dohme |
AMIDOPYRAZOLHEMMER OF INTERLEUKIN RECEPTOR-MEDIATED KINASES
|
|
JP2014517079A
(ja)
|
2011-06-22 |
2014-07-17 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
Ａｔｒキナーゼ阻害剤として有用な化合物
|
|
UA109614C2
(uk)
*
|
2011-12-30 |
2015-09-10 |
|
ПОХІДНІ ТІЄНО[3,2-d]ПІРИМІДИНУ, ЩО МАЮТЬ ІНГІБУЮЧУ АКТИВНІСТЬ ВІДНОСНО ПРОТЕЇНКІНАЗ
|
|
HK1209632A1
(en)
*
|
2012-01-10 |
2016-04-08 |
林伯士艾瑞斯公司 |
Irak inhibitors and uses thereof
|
|
CN104159904B
(zh)
*
|
2012-01-10 |
2016-12-14 |
霍夫曼-拉罗奇有限公司 |
噻吩并嘧啶化合物
|
|
WO2014003483A1
(en)
*
|
2012-06-29 |
2014-01-03 |
Hanmi Pharm. Co., Ltd. |
Fused pyrimidine derivatives having inhibitory activity on fms kinases
|
|
RU2015104123A
(ru)
|
2012-07-10 |
2016-08-27 |
Арес Трейдинг С.А. |
Производные пиримидинпиразолила
|
|
WO2014011911A2
(en)
*
|
2012-07-11 |
2014-01-16 |
Nimbus Iris, Inc. |
Irak inhibitors and uses thereof
|
|
CN104902959A
(zh)
|
2012-07-11 |
2015-09-09 |
林伯士艾瑞斯公司 |
Irak抑制剂和其用途
|
|
EP2872144A4
(en)
|
2012-07-11 |
2015-12-02 |
Nimbus Iris Inc |
IRAQ INHIBITOR AND USES THEREOF
|
|
EP3418281B1
(en)
|
2012-12-07 |
2020-09-30 |
Vertex Pharmaceuticals Inc. |
Pyrazolo[1,5-a]pyrimidines useful as inhibitors of atr kinase for the treatment of cancer diseases
|
|
BR112015014034A2
(pt)
|
2013-01-10 |
2017-07-11 |
Nimbus Iris Inc |
inibidores de irak e usos dos mesmos
|
|
WO2014110574A1
(en)
|
2013-01-14 |
2014-07-17 |
Incyte Corporation |
Bicyclic aromatic carboxamide compounds useful as pim kinase inhibitors
|
|
UA121098C2
(uk)
|
2013-01-15 |
2020-04-10 |
Інсайт Холдинґс Корпорейшн |
Тіазолкарбоксаміди і піридинкарбоксаміди, які використовуються як інгібітори рім-кінази
|
|
US8778365B1
(en)
|
2013-01-31 |
2014-07-15 |
Merz Pharmaceuticals, Llc |
Topical compositions and methods for making and using same
|
|
EP2970288A1
(en)
*
|
2013-03-15 |
2016-01-20 |
Vertex Pharmaceuticals Incorporated |
Compounds useful as inhibitors of atr kinase
|
|
EP2970286A1
(en)
|
2013-03-15 |
2016-01-20 |
Vertex Pharmaceuticals Inc. |
Fused pyrazolopyrimidine derivatives useful as inhibitors of atr kinase
|
|
JP2016512239A
(ja)
|
2013-03-15 |
2016-04-25 |
バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ |
Ａｔｒキナーゼの阻害剤として有用な化合物
|
|
GB201311888D0
(en)
|
2013-07-03 |
2013-08-14 |
Glaxosmithkline Ip Dev Ltd |
Novel compounds
|
|
GB201311891D0
(en)
|
2013-07-03 |
2013-08-14 |
Glaxosmithkline Ip Dev Ltd |
Novel compound
|
|
WO2015006181A1
(en)
|
2013-07-11 |
2015-01-15 |
Merck Sharp & Dohme Corp. |
Substituted amidopyrazole inhibitors of interleukin receptor-associated kinases (irak-4)
|
|
WO2015027124A1
(en)
*
|
2013-08-23 |
2015-02-26 |
Incyte Corporation |
Furo- and thieno-pyridine carboxamide compounds useful as pim kinase inhibitors
|
|
EP3049086A4
(en)
|
2013-09-27 |
2017-02-22 |
Nimbus Iris, Inc. |
Irak inhibitors and uses thereof
|
|
EP3077397B1
(en)
|
2013-12-06 |
2019-09-18 |
Vertex Pharmaceuticals Inc. |
2-amino-6-fluoro-n-[5-fluoro-pyridin-3-yl]pyrazolo[1,5-a]pyrimidin-3-carboxamide compound useful as atr kinase inhibitor, its preparation, different solid forms and radiolabelled derivatives thereof
|
|
USRE50030E1
(en)
|
2013-12-13 |
2024-07-02 |
Dana-Farber Cancer Institute, Inc. |
Methods to treat lymphoplasmacytic lymphoma
|
|
WO2015089481A2
(en)
|
2013-12-13 |
2015-06-18 |
Dana-Farber Cancer Institute, Inc. |
Methods to treat lymphoplasmacytic lymphoma
|
|
TWI667233B
(zh)
|
2013-12-19 |
2019-08-01 |
德商拜耳製藥公司 |
新穎吲唑羧醯胺，其製備方法、含彼等之醫藥製劑及其製造醫藥之用途
|
|
HK1231480A1
(zh)
|
2014-01-10 |
2017-12-22 |
Aurigene Discovery Technologies Limited |
作为irak4抑制剂的吲唑化合物
|
|
PT3805233T
(pt)
|
2014-01-13 |
2024-04-15 |
Aurigene Oncology Ltd |
Enantiómeros (r) e (s) de n-(5-(3-hidroxipirrolidin-1-il)-2 morfolinooxazolo[4,5-b]piridin-6-il)-2-(2-metilpiridin-4-il)oxazole-carboxamida como inibidores de irak4 para o tratamento de cancro
|
|
US20180228907A1
(en)
|
2014-04-14 |
2018-08-16 |
Arvinas, Inc. |
Cereblon ligands and bifunctional compounds comprising the same
|
|
HRP20210935T1
(hr)
|
2014-05-23 |
2021-08-06 |
F. Hoffmann - La Roche Ag |
Spojevi 5-kloro-2-difluorometoksifenil pirazolopirimidina koji predstavljaju inhibitore jak
|
|
ES2777608T3
(es)
|
2014-06-05 |
2020-08-05 |
Vertex Pharma |
Derivados radiomarcados de un compuesto de 2-amino-6-fluoro-N-[5-fluoro-piridin-3-il]-pirazolo[1,5-a]pirimidin-3-carboxamida útiles como inhibidores de ATR cinasa, la preparación de dicho compuesto y diferentes formas sólidas del mismo
|
|
CA2950780C
(en)
|
2014-06-17 |
2023-05-16 |
Vertex Pharmaceuticals Incorporated |
Method for treating cancer using a combination of chk1 and atr inhibitors
|
|
WO2016010897A1
(en)
|
2014-07-14 |
2016-01-21 |
Incyte Corporation |
Bicyclic heteroaromatic carboxamide compounds useful as pim kinase inhibitors
|
|
US9580418B2
(en)
|
2014-07-14 |
2017-02-28 |
Incyte Corporation |
Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
|
|
EP3715346B1
(en)
|
2014-10-22 |
2024-01-03 |
Dana-Farber Cancer Institute, Inc. |
Thiazolyl-containing compounds for treating proliferative diseases
|
|
US20170333435A1
(en)
|
2014-11-06 |
2017-11-23 |
Lysosomal Therapeutics Inc. |
Substituted imidazo[1,5-a]pyrimidines and their use in the treatment of medical disorders
|
|
WO2016073891A1
(en)
|
2014-11-06 |
2016-05-12 |
Lysosomal Therapeutics Inc. |
Substituted pyrrolo[1,2-a]pyrimidines and their use in the treatment of medical disorders
|
|
DK3215511T3
(da)
|
2014-11-06 |
2024-05-13 |
Bial R&D Invest S A |
Substituerede pyrazolo(1,5-a)pyrimidiner og deres anvendelse i behandlingen af medicinske lidelser
|
|
LT3221306T
(lt)
*
|
2014-11-20 |
2020-03-10 |
Merck Patent Gmbh |
Heteroarilo junginiai, kaip irak inhibitoriai ir jų panaudojimas
|
|
EP3267996B1
(en)
*
|
2015-03-12 |
2020-11-11 |
Merck Sharp & Dohme Corp. |
Pyrazolopyrimidine inhibitors of irak4 activity
|
|
WO2016144847A1
(en)
*
|
2015-03-12 |
2016-09-15 |
Merck Sharp & Dohme Corp. |
Pyrrolopyridazine inhibitors of irak4 activity
|
|
US10040802B2
(en)
|
2015-03-12 |
2018-08-07 |
Merck Sharp & Dohme Corp. |
Thienopyrazine inhibitors of IRAK4 activity
|
|
US10155765B2
(en)
|
2015-03-12 |
2018-12-18 |
Merck Sharp & Dohme Corp. |
Carboxamide inhibitors of IRAK4 activity
|
|
WO2016144848A1
(en)
*
|
2015-03-12 |
2016-09-15 |
Merck Sharp & Dohme Corp. |
Pyrrolotriazine inhibitors of irak4 activity
|
|
WO2016196244A1
(en)
|
2015-05-29 |
2016-12-08 |
Incyte Corporation |
Pyridineamine compounds useful as pim kinase inhibitors
|
|
WO2017004134A1
(en)
*
|
2015-06-29 |
2017-01-05 |
Nimbus Iris, Inc. |
Irak inhibitors and uses thereof
|
|
HK1249509A1
(zh)
*
|
2015-07-15 |
2018-11-02 |
Aurigene Discovery Technologies Limited |
作为irak-4抑制剂的吲唑及氮杂吲唑化合物
|
|
TWI734699B
(zh)
|
2015-09-09 |
2021-08-01 |
美商英塞特公司 |
Ｐｉｍ激酶抑制劑之鹽
|
|
CN108348512B
(zh)
*
|
2015-09-17 |
2021-09-03 |
希望之城 |
Pcna抑制剂
|
|
WO2017059357A1
(en)
|
2015-09-30 |
2017-04-06 |
Vertex Pharmaceuticals Incorporated |
Method for treating cancer using a combination of dna damaging agents and atr inhibitors
|
|
CN105237414B
(zh)
*
|
2015-09-30 |
2017-03-22 |
浙江永宁药业股份有限公司 |
ivacaftor中间体及其制备方法和用途
|
|
WO2017059251A1
(en)
|
2015-10-02 |
2017-04-06 |
Incyte Corporation |
Heterocyclic compounds useful as pim kinase inhibitors
|
|
CN108473498B
(zh)
*
|
2015-12-22 |
2021-11-02 |
豪夫迈·罗氏有限公司 |
作为IRAK4调节剂的吡唑并[1,5a]嘧啶衍生物
|
|
JP7038063B2
(ja)
|
2016-04-06 |
2022-03-17 |
リソソーマル・セラピューティクス・インコーポレイテッド |
ピラゾロ［１，５－ａ］ピリミジニルカルボキサミド化合物および医学的障害の処置におけるその使用
|
|
EP3440083A4
(en)
|
2016-04-06 |
2019-09-18 |
Lysosomal Therapeutics Inc. |
IMIDAZO [1,5-A] PYRIMIDINYL-CARBOXAMIDE COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDER
|
|
EP3440081A4
(en)
|
2016-04-06 |
2019-09-18 |
Lysosomal Therapeutics Inc. |
PYRROLO [1,2-A] PYRIMIDINYL-CARBOXAMIDE COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDER
|
|
EP3452045A1
(en)
*
|
2016-05-04 |
2019-03-13 |
Lysosomal Therapeutics Inc. |
Methods of treatment and combination therapies using gcase activator heterobicyclic and related compounds
|
|
US11345698B2
(en)
|
2016-05-05 |
2022-05-31 |
Bial—R&D Investments, S.A. |
Substituted imidazo[1,2-a]pyridines, substituted imidazo[1,2-a]pyrazines, related compounds, and their use in the treatment of medical disorders
|
|
AU2017261291C1
(en)
|
2016-05-05 |
2022-05-26 |
Bial - R&D Investments, S.A. |
Substituted imidazo[1,2-b]pyridazines, substituted imidazo[1,5-b]pyridazines, related compounds, and their use in the treatment of medical disorders
|
|
CN106222183B
(zh)
*
|
2016-07-25 |
2019-11-08 |
南通大学 |
靶向人irak1基因的小干扰rna及其应用
|
|
EP3535273A1
(en)
|
2016-11-02 |
2019-09-11 |
H. Hoffnabb-La Roche Ag |
PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS
|
|
ES2902885T3
(es)
*
|
2017-02-01 |
2022-03-30 |
Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd |
Derivados de N1-(4-(5-(ciclopropilmetil)-1-metil-1H-pirazol-4-il)piridin-2-il)ciclohexano-1,4-diamina y compuestos relacionados como inhibidores de CK1 y/o IRAK1 para el tratamiento del cáncer
|
|
JOP20180011A1
(ar)
|
2017-02-16 |
2019-01-30 |
Gilead Sciences Inc |
مشتقات بيرولو [1، 2-b]بيريدازين
|
|
CA3056893A1
(en)
|
2017-03-31 |
2018-10-04 |
Aurigene Discovery Technologies Limited |
Compounds and compositions for treating hematological disorders
|
|
CN106946890A
(zh)
*
|
2017-04-26 |
2017-07-14 |
中国药科大学 |
吡啶类irak4抑制剂、其制备方法及应用
|
|
CA3061236A1
(en)
|
2017-05-22 |
2018-11-29 |
F. Hoffmann-La Roche Ag |
Therapeutic compounds and compositions, and methods of use thereof
|
|
CN111094292A
(zh)
|
2017-06-21 |
2020-05-01 |
豪夫迈·罗氏有限公司 |
作为IRAK4调节剂的吡唑并[1,5a]嘧啶衍生物
|
|
JP2020524663A
(ja)
*
|
2017-06-21 |
2020-08-20 |
エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ |
Ｉｒａｋ４調節因子としてのイソインドリノン誘導体
|
|
CN110770229A
(zh)
*
|
2017-06-21 |
2020-02-07 |
豪夫迈·罗氏有限公司 |
作为irak4调节剂的苯并呋喃化合物
|
|
WO2019001460A1
(zh)
*
|
2017-06-27 |
2019-01-03 |
南京明德新药研发股份有限公司 |
作为 irak4 抑制剂的稠环化合物
|
|
JP7114394B2
(ja)
*
|
2017-08-18 |
2022-08-08 |
住友化学株式会社 |
化合物、レジスト組成物及びレジストパターンの製造方法
|
|
WO2019060693A1
(en)
|
2017-09-22 |
2019-03-28 |
Kymera Therapeutics, Inc. |
CRBN LIGANDS AND USES THEREOF
|
|
JP7366031B2
(ja)
|
2017-09-22 |
2023-10-20 |
カイメラ セラピューティクス， インコーポレイテッド |
タンパク質分解剤およびそれらの使用
|
|
RS65572B1
(sr)
|
2017-10-31 |
2024-06-28 |
Curis Inc |
Inhibitor irak4 u kombinaciji sa inhibitorom bcl-2 za upotrebu u lečenju kancera
|
|
WO2019099926A1
(en)
|
2017-11-17 |
2019-05-23 |
Arvinas, Inc. |
Compounds and methods for the targeted degradation of interleukin-1 receptor-associated kinase 4 polypeptides
|
|
US11492357B2
(en)
|
2017-11-30 |
2022-11-08 |
Hanmi Pharm. Co., Ltd. |
Thieno[3,2-d]pyrimidine derivative compound having inhibitory activity for protein kinase
|
|
AR113922A1
(es)
|
2017-12-08 |
2020-07-01 |
Incyte Corp |
Terapia de combinación de dosis baja para el tratamiento de neoplasias mieloproliferativas
|
|
WO2019111218A1
(en)
|
2017-12-08 |
2019-06-13 |
Cadila Healthcare Limited |
Novel heterocyclic compounds as irak4 inhibitors
|
|
IL315310A
(en)
|
2017-12-26 |
2024-10-01 |
Kymera Therapeutics Inc |
Irak degraders and uses thereof
|
|
WO2019140380A1
(en)
|
2018-01-12 |
2019-07-18 |
Kymera Therapeutics, Inc. |
Protein degraders and uses thereof
|
|
WO2019140387A1
(en)
|
2018-01-12 |
2019-07-18 |
Kymera Therapeutics, Inc. |
Crbn ligands and uses thereof
|
|
WO2019192962A1
(en)
*
|
2018-04-05 |
2019-10-10 |
Merck Patent Gmbh |
Heteroaryl compounds as type ii irak inhibitors and uses hereof
|
|
US11292792B2
(en)
|
2018-07-06 |
2022-04-05 |
Kymera Therapeutics, Inc. |
Tricyclic CRBN ligands and uses thereof
|
|
EP3817822A4
(en)
|
2018-07-06 |
2022-07-27 |
Kymera Therapeutics, Inc. |
PROTEIN DEGRADANTS AND USES THEREOF
|
|
TWI721483B
(zh)
|
2018-07-13 |
2021-03-11 |
美商基利科學股份有限公司 |
吡咯并[1,2-b]嗒𠯤衍生物
|
|
CN110862375B
(zh)
*
|
2018-08-27 |
2022-10-25 |
深圳铂立健医药有限公司 |
吡唑化合物及其药物组合物和应用
|
|
EP3873911A4
(en)
|
2018-10-30 |
2022-06-22 |
Kronos Bio, Inc. |
COMPOUNDS, COMPOSITIONS AND METHODS OF MODULATING CDK9 ACTIVITY
|
|
KR20250167680A
(ko)
|
2018-11-30 |
2025-12-01 |
카이메라 쎄라퓨틱스 인코포레이티드 |
Irak 분해제 및 이의 용도
|
|
JOP20210322A1
(ar)
*
|
2019-06-27 |
2023-01-30 |
Biogen Ma Inc |
مشتقات من إيميدازو[1 ،2-a] بيريدينيل واستخدامها في علاج مرض
|
|
WO2021066559A1
(en)
|
2019-10-02 |
2021-04-08 |
Kainos Medicine, Inc. |
N-(1h-imidazol-2-yl)benzamide compound and pharmaceutical composition comprising the same as active ingredient
|
|
US11591332B2
(en)
|
2019-12-17 |
2023-02-28 |
Kymera Therapeutics, Inc. |
IRAK degraders and uses thereof
|
|
WO2021127190A1
(en)
|
2019-12-17 |
2021-06-24 |
Kymera Therapeutics, Inc. |
Irak degraders and uses thereof
|
|
CA3177852A1
(en)
|
2020-04-04 |
2021-10-07 |
Pfizer Inc. |
Methods of treating coronavirus disease 2019
|
|
TW202210483A
(zh)
|
2020-06-03 |
2022-03-16 |
美商凱麥拉醫療公司 |
Irak降解劑之結晶型
|
|
EP4223750B1
(en)
*
|
2020-09-30 |
2025-06-25 |
Asahi Kasei Pharma Corporation |
Nitrogen-containing bicyclic compounds which contain pyrimidine as interleukin 1 receptor-associated kinase 4 (irak-4) inhibitors to be used in the treatment of inflammatory or autoimmune diseases
|
|
US11866405B2
(en)
|
2020-12-10 |
2024-01-09 |
Astrazeneca Ab |
Substituted indazoles as IRAK4 inhibitors
|
|
JP2024503300A
(ja)
|
2020-12-30 |
2024-01-25 |
カイメラ セラピューティクス， インコーポレイテッド |
Ｉｒａｋ分解剤およびそれらの使用
|
|
CN116867494A
(zh)
|
2021-02-15 |
2023-10-10 |
凯麦拉医疗公司 |
Irak4降解剂和其用途
|
|
TW202245788A
(zh)
|
2021-02-15 |
2022-12-01 |
美商凱麥拉醫療公司 |
Irak4降解劑及其用途
|
|
US12178821B2
(en)
|
2021-04-08 |
2024-12-31 |
Curis, Inc. |
Combination therapies for the treatment of cancer
|
|
WO2022236058A1
(en)
|
2021-05-07 |
2022-11-10 |
Kymera Therapeutics, Inc. |
Cdk2 degraders and uses thereof
|
|
KR102869914B1
(ko)
*
|
2021-10-28 |
2025-10-13 |
재단법인 대구경북첨단의료산업진흥재단 |
신규한 티에노[2,3-d]피리미딘 유도체, 이의 제조방법 및 이를 유효성분으로 포함하는 암 또는 자가면역질환의 예방 또는 치료용 약학적 조성물
|
|
AU2022378630A1
(en)
|
2021-10-29 |
2024-05-09 |
Kymera Therapeutics, Inc. |
Irak4 degraders and synthesis thereof
|
|
JP2025504059A
(ja)
|
2022-01-31 |
2025-02-06 |
カイメラ セラピューティクス， インコーポレイテッド |
Ｉｒａｋデグレーダー及びその使用
|